Prion Disease
MarketVue®: Prion Disease
The MarketVue®: Prion Disease market landscape report combines primary (KOL interviews) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology
Research for the MarketVue®: Prion Disease report is supported by 8 qualitative interviews with key opinion leaders and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)
Key companies mentioned
• Ionis Pharmaceuticals
• Sangamo Therapeutics
• Gate Bioscience
Key drugs mentioned
• Antiepileptics (levetiracetam, sodium valproate)
• Long-acting benzodiazepines (clonazepam, diazepam)
• Antipsychotics (quetiapine, risperidone, olanzapine)
• Benzodiazepines (oxazepam, temazepam, alprazolam)
• Sedatives (trazadone, mirtazapine)
• ION717
• hSYN1-ZF-R
Please note: the online download version of this report is for a global site license.
- 1. DISEASE OVERVIEW
- Figure 1.1. Prion disease pathophysiology
- Table 1.1. Human prion diseases
- 2. EPIDEMIOLOGY
- Figure 2.1. Incident cases of prion disease by region (2023)
- Table 2.1. Diagnosed symptomatic incident cases of prion diseases in the U.S. and EU5 (2023)
- Figure 2.2. Distribution of types of prion disease
- Figure 2.3. Average months from prion disease onset of symptoms to death
- Figure 2.4. Trends in prion disease incidence
- 3. DIAGNOSIS & CURRENT TREATMENT
- Figure 3.1. Diagnostic pathway for prion disease
- Figure 3.2. Neurologist estimates of diagnosis in prion diseases (n=4)
- Figure 3.3. Key recent advancements in prion disease diagnosis
- Figure 3.4. Neurologist rates of genetic testing in prion disease patients (n=8)
- Figure 3.5. Drivers and barriers of genetic testing in prion disease patients
- Table 3.1. Prion disease symptoms
- Figure 3.6. Defining disease severity in prion disease
- Table 3.2. Treatment goals for prion disease
- Table 3.3. Pharmacological and non-pharmacological symptom control approaches for prion disease
- 4. UNMET NEED
- Figure 4.1. Top unmet needs in prion disease
- Figure 4.2. Neurologist-reported level of unmet need for novel prion disease treatments (n=8)
- 5. PIPELINE ANALYSIS
- Table 5.1. Comparison of ongoing trials of therapies for prion disease
- Figure 5.1. Ionis ASO pre-clinical data
- Figure 5.2. Comparison of target prion disease patient populations
- 6. VALUE & ACCESS
- Table 6.1. Pricing analogues for prion disease
- 7. METHODOLOGY
- Primary Market Research Approach
- Epidemiology
- Value and Access
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook